The use of molecular diagnostics in bladder cancer.

Bladder cancer is a common disease that causes significant morbidity and mortality in the United States. Early detection and routine surveillance are recommended in the management of this chronic and recurrent disease. Cystoscopic examination has been used for detection and follow-up; however, it is costly and is associated with patient discomfort. With advances in molecular biology and biochemistry, many diagnostic assays have been developed to supplement cystoscopy. The mechanisms and variable results of these assays are described. In addition, the economic and social implications of bladder cancer detection and surveillance are discussed.

[1]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[2]  G. Papanicolaou,et al.  URINE SEDIMENT SMEARS AS A DIAGNOSTIC PROCEDURE IN CANCERS OF THE URINARY TRACT. , 1945, Science.

[3]  J. Briggman,et al.  Utilization of nuclear matrix proteins for cancer diagnosis. , 1996, Critical reviews in eukaryotic gene expression.

[4]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[5]  D J O'Kane,et al.  Comparison of screening methods in the detection of bladder cancer. , 1999, The Journal of urology.

[6]  D. Lamm,et al.  A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. , 1997, Journal of Urology.

[7]  P. Schellhammer,et al.  Improved detection of recurrent bladder cancer using the Bard BTA stat Test. , 1998, Urology.

[8]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[9]  P. Abel.  Prognostic indices in transitional cell carcinoma of the bladder. , 1988, British journal of urology.

[10]  G. Murphy,et al.  Further study of fibrinogen degradation products in bladder cancer detection. , 1978, Urology.

[11]  T. Zein,et al.  Cytologic spectrum of bladder cancer. , 1984, Urology.

[12]  M. Rahat,et al.  Telomerase activity in patients with transitional cell carcinoma , 1999, Cancer.

[13]  M. Hanna,et al.  A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products. , 1984, Cancer research.

[14]  M. Marberger,et al.  Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. , 1999, The Journal of urology.

[15]  D. Cowan,et al.  Correlation of histopathological, cytological and flow cytometric findings in neoplastic and nonneoplastic lesions of the bladder. , 1987, The Journal of urology.

[16]  L. Baert,et al.  Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. , 1996, The Journal of urology.

[17]  B. Liu,et al.  Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. , 1999, Urology.

[18]  N. Block,et al.  Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. , 1997, Cancer research.

[19]  O. Cussenot,et al.  Assessment of microsatellite instability in urine in the detection of transitional‐cell carcinoma of the bladder , 1998, International journal of cancer.

[20]  Marek Kimmel,et al.  The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma , 1987, Cancer.

[21]  D. Pode,et al.  Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. , 1998, The Journal of urology.

[22]  H. Leyh,et al.  Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. , 1997, European urology.

[23]  M. Droller,et al.  Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity , 1998, Cancer.

[24]  E. Messing,et al.  Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. , 1996, The Journal of urology.

[25]  A. Agarwal,et al.  NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. , 1999, Anticancer research.

[26]  C. Öbek,et al.  Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. , 1997, Cancer research.

[27]  H. Grossman,et al.  Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. , 1998, The Journal of urology.

[28]  J. Irani,et al.  BTA stat and BTA TRAK: A Comparative Evaluation of Urine Testing for the Diagnosis of Transitional Cell Carcinoma of the Bladder , 1999, European Urology.

[29]  Y S Erozan,et al.  Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis , 1996, Science.

[30]  D. Biasoni,et al.  Evaluation of Urinary Level of NMP22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test , 1999, European Urology.

[31]  W. Ellis,et al.  Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. , 1997, Urology.

[32]  G. Murphy,et al.  Evaluation of biological markers in bladder cancer. , 1975, The Journal of urology.

[33]  Y S Erozan,et al.  Microsatellite alterations as clonal markers for the detection of human cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Sternberg,et al.  Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. , 1997, Urology.

[35]  F. Meyer,et al.  Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. , 1997, The Journal of urology.

[36]  R. Kinders,et al.  Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Melamed,et al.  Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. , 1990, The Journal of urology.

[38]  M F Sarosdy,et al.  Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. , 1996, The Journal of urology.

[39]  S. Kagawa,et al.  Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. , 1998, British journal of urology.

[40]  B. Blumenstein,et al.  Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. , 1997, Urology.

[41]  Kazuhiro Yoshida,et al.  Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine , 1997, Cancer.

[42]  M. Lundie,et al.  Rapid detection of bladder cancer: a comparative study of point of care tests. , 1997, The Journal of urology.

[43]  P. Schellhammer,et al.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. , 1995, The Journal of urology.

[44]  M. Soloway,et al.  Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. , 1986, The Journal of urology.

[45]  M. Benson,et al.  The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder. , 1992, The Journal of urology.